No Data
No Data
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Hualing Pharmaceutical's second-generation GKA launches phase 1 clinical trial in the US and completes the enrollment of the first patient
Glonghui, April 26 | Hualing Pharmaceutical (2552.HK) announced that the first phase clinical trial of a second-generation glucokinase activator (second-generation GKA) has officially started in the US, and the first case was enrolled on April 25, local time in the US. The trial was a randomized, double-blind, placebo-controlled, single-dose escalation pharmacokinetics and pharmacodynamics study in 40 US patients with type 2 diabetes (T2D). The second-generation GKA is a new molecular entity with optimized physico-chemical properties. Using Hualing Pharmaceutical's proprietary formulation technology, it is designed for oral administration once a day. Second generation GKA
華領醫藥-B:年報 2023
Changes in Hong Kong stocks | Hualing Pharmaceutical-B (02552.HK) rose more than 12%, the company had plenty of cash in hand, and second-generation GKA's clinical practice progressed smoothly in the US
Hualing Pharmaceutical-B (02552.HK) rose by more than 12%. As of press release, it rose 12.24% to HK$1.65, with a turnover of HK$2.11,400.
Hualing Pharmaceutical (02552) announces 2023 results: R&D expenses of about 172 million yuan to actively promote the overseas market layout of second-generation GKA
On March 28, Hualing Pharmaceutical (02552) announced its 2023 results
No Data